INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 44h ago
HOUSE PTR4h ago
SEC 13F4h ago
ROBINHOOD CHAIN4h ago
SEC FORM 4/Option exerciseVerified data

Greenstreet Yvonne reported ALNY

Director, Chief Executive Officer · ALNYLAM PHARMACEUTICALS, INC. · ALNYLAM PHARMACEUTICALS, INC. — Stock Option (right to buy)

Side
M
Value
—
Shares
839
Price
—
Executed
Nov 26, 2025
Disclosed
Dec 1, 2025
Disclosure timeline5 days from execution to publication · legal deadline 2 business days
Nov 26 executedDec 1, 2025 disclosed

ALNY · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
8/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Option exercise — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing+6 / 15

    Disclosed 3 business days after execution (deadline: 2)

  • Historical behavior+1 / 15

    Routine: 20 prior trades recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · ALNY

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    36
    TT
    Tanguler TolgaEVP, Chief Commercial Officer
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$5,667
    15 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    19
    GP
    Garg PushkalEVP Chief R&D
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Grant or award
    		A—
    3,800 sh
    		Jan 11, 2026Jan 14, 2026
    traded Jan 11, 2026
    		+3dSEC FORM 4

    Evidence

    36
    GP
    Garg PushkalEVP Chief R&D
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$34K
    96 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    36
    GP
    Garg PushkalEVP Chief R&D
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$44K
    123 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    36
    GP
    Garg PushkalEVP Chief R&D
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$26K
    73 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    36
    GP
    Garg PushkalEVP Chief R&D
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$17K
    47 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    39
    GP
    Garg PushkalEVP Chief R&D
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$73K
    199 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    36
    GP
    Garg PushkalEVP Chief R&D
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$15K
    40 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    36
    GP
    Garg PushkalEVP Chief R&D
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$6,676
    18 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    36
    GP
    Garg PushkalEVP Chief R&D
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$5,242
    14 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    36
    GP
    Garg PushkalEVP Chief R&D
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$5,667
    15 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    16
    GY
    Greenstreet YvonneDirector, Chief Executive Officer
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Grant or award
    		A—
    19.0K sh
    		Jan 11, 2026Jan 14, 2026
    traded Jan 11, 2026
    		+3dSEC FORM 4

    Evidence

    32
    GY
    Greenstreet YvonneDirector, Chief Executive Officer
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$87K
    247 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    32
    GY
    Greenstreet YvonneDirector, Chief Executive Officer
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$96K
    269 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    32
    GY
    Greenstreet YvonneDirector, Chief Executive Officer
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$94K
    263 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    32
    GY
    Greenstreet YvonneDirector, Chief Executive Officer
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$217K
    607 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    35
    GY
    Greenstreet YvonneDirector, Chief Executive Officer
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$279K
    778 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    32
    GY
    Greenstreet YvonneDirector, Chief Executive Officer
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$193K
    537 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    35
    GY
    Greenstreet YvonneDirector, Chief Executive Officer
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$353K
    980 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    32
    GY
    Greenstreet YvonneDirector, Chief Executive Officer
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$226K
    624 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001735276-25-000125
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Nov 26, 2025
    Published
    Dec 1, 2025
    Ingested by INSIDER
    Nov 5, 04:30 UTC
    Last re-read
    Nov 5, 04:30 UTC

    Extracted facts

    Filer
    Greenstreet Yvonne
    Role
    Director, Chief Executive Officer
    Transaction
    Option exerciseAs filed: “M”
    Asset
    ALNYLAM PHARMACEUTICALS, INC. — Stock Option (right to buy)
    Ticker
    ALNY
    Shares
    839
    Price per share
    $0
    Execution date (reported)
    Nov 26, 2025
    Owned after transaction
    0 shares
    Days from execution to publication
    5

    What this establishes

    Greenstreet Yvonne filed this Form 4 reporting a option exercise of ALNY on Nov 26, 2025. It became public on Dec 1, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, Chief Executive Officer
    Greenstreet Yvonnecik:0001446125
    Issuer
    ALNYLAM PHARMACEUTICALS, INC.cik:0001178670

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.